Harrow, Inc. splits its revenue into 2 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Branded at $56.1 million, 79% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
276
|
71
|
44
|
89
|
72
|
64
|
48
|
67
|
49
|
| Branded |
213
+46.6%
share 77.1%
|
56
+32.7%
share 79.4%
|
31
+10.5%
share 69.5%
|
74
+60.0%
share 83.2%
|
52
+80.7%
share 72.0%
|
42
share 66.3%
|
28
share 58.1%
|
46
share 69.3%
|
29
share 58.0%
|
| Compounding |
63
-23.7%
share 22.9%
|
15
-32.2%
share 20.6%
|
13
-32.7%
share 30.5%
|
15
-27.0%
share 16.8%
|
20
-3.1%
share 28.0%
|
21
share 33.7%
|
20
share 41.9%
|
20
share 30.7%
|
21
share 42.0%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HROW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Nashville, TN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1360214
- Former names
- HARROW HEALTH, INC. (until Sep 20, 2023); Imprimis Pharmaceuticals, Inc. (until Dec 17, 2018); TRANSDEL PHARMACEUTICALS INC (until Feb 27, 2012); Bywater Resources, Inc (until Sep 12, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.